New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements on key outcomes in people with dementia with Lewy bodies (DLB). In the ...

Ms. Davis is the author of “Floating in the Deep End: How Caregivers Can See Beyond Alzheimer’s.” In the photograph I’m sitting beside my father, a decorated Christmas tree behind us, as he looks at a ...

“Pure play” digital asset treasury companies will have to contend with volatility tied to the net asset value of their token holdings if they don’t build successful business ventures. The rise of ...

Accenture is acquiring a majority stake in DLB Associates, an artificial-intelligence data center engineering and consulting firm. The global consultancy said Tuesday that it was buying a 65% stake in ...

Accenture plc (NYSE: ACN) erased earlier gains Tuesday as investors weighed analyst optimism against acquisition news. The consulting firm initially rose after Morgan Stanley upgraded the stock and ...

Accenture (NYSE: ACN) signed an agreement to acquire a majority stake (65%) in US-based AI data center engineering and consulting firm DLB Associates and its affiliated companies (collectively “DLB”).

Please provide your email address to receive an email when new articles are posted on . The introduction of additional neflamapimod in an open-label extension led to significant clinical improvements.

Neflamapimod, an experimental, oral drug targeting neuroinflammation being developed by CervoMed, led to a significant reduction in a key blood biomarker of neurodegeneration, which correlated with a ...

Investors in Dolby Laboratories Inc (Symbol: DLB) saw new options begin trading today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DLB ...

Dolby Laboratories, Inc. (NYSE:DLB) Q4 2025 Earnings Call Transcript November 18, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $0.99, expectations were $0.7. Operator: ...